MicroRNA Profiling Can Classify Acute Leukemias of Ambiguous Lineage as Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia

Leeuw, David C. de; Ancker, Willemijn van den; Denkers, Fedor; Menezes, Renée X. de; Westers, Theresia M.; Ossenkoppele, Gert J.; Loosdrecht, Arjan A. van de; Smit, Linda

doi:10.1158/1078-0432.ccr-12-3657

Cited by 38 publications

(23 citation statements)

References 28 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miRNAbased integrated analyses have provided new perspectives for clinical validation of the association between miRNA expression patterns and tumor grades or specific subtypes, highlighting the potential values of miRNAs in diagnosis and subclassification (29)(30)(31). Our present data indicated that miR-663 was differently expressed in 17 grade I glioma, 52 grade II glioma, 62 grade III glioma, and 125 glioblastoma (grade IV) specimens, suggesting that miR-663 was a potential molecular biomarker in distinguishing tumor grades.…”

Section: The Reduced Mir-663 Expression Correlates With the High Levementioning

confidence: 53%

Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma

Shi

Chen

Zhang

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To determine the prognostic significance of miR-663 in glioblastoma, its effect in tumor progression, and the underlying mechanism.Experimental Design: Specimens from 256 cases of patients with glioma, including 239 patients with follow-up information, were used to analyze the association between miR-663 and patients' prognosis by Kaplan-Meier and multivariate Cox regression analyses. The effects of miR-663 on glioblastoma cell proliferation and invasion were examined both in vitro and in vivo. Bioinformatics prediction and signal network analysis were applied to identify the putative targets of miR-663, which were further verified by luciferase reporter assay, rescue experiments as well as the immunohistochemistry (IHC) and Western blotting examination of downstream effectors. Quantitative reverse transcriptase PCR (qRT-PCR) and IHC were applied to investigate the clinical association between miR-663 and its target in human glioblastoma specimens.Results: miR-663 was inversely correlated with glioma grades but positively correlated with patients' survival. Furthermore, two distinct subgroups of patients with glioblastoma with different prognoses were identified on the basis of miR-663 expression in our specimens and that from The Cancer Genome Atlas (TCGA) database. Overexpression of miR-663 significantly suppressed the proliferation and invasion of glioblastoma cells in vitro and in vivo. Mechanistically, we discovered PIK3CD as a direct target of miR-663 and found that phosphorylated AKT and three key downstream effectors of PIK3CD, i.e., CCND1, MMP2, and MMP7, were downregulated by miR-663 overexpression. Moreover, PIK3CD was inversely correlated with miR-663 in glioblastoma specimens and predicted poor prognosis of patients with glioblastoma.Conclusion: miR-663 is a novel prognostic biomarker and a potential therapeutic candidate for glioblastoma. Clin Cancer Res; 20(7); 1803-13. Ó2014 AACR.

show abstract

Section: The Reduced Mir-663 Expression Correlates With the High Levementioning

confidence: 53%

Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma

Shi

Chen

Zhang

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Different gene expression patterns have been found between MPAL and other ALs when using the EGIL or the 2008 WHO criteria [18]. However, contrary to previous studies, de Leeuw et al [29] found that microRNA expression profiles categorized AL of ambiguous lineage as either AML or ALL, rather than distinct group.…”

Section: Discussionmentioning

confidence: 99%

Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used

et al. 2016

View full text Add to dashboard Cite

BackgroundDifferent criteria have been used to diagnose mixed-phenotype acute leukemia (MPAL), which has impacted the number of individuals diagnosed with this pathology. Better outcomes have been reported when using acute lymphoblastic leukemia (ALL)-type chemotherapy in the treatment of MPAL.MethodsWe compared the outcome of 4 groups of patients with MPAL. Group 1 included patients diagnosed using the 2008/2016 World Health Organization (WHO) classification; group 2 included patients diagnosed using the European Group for the Immunological Characterization of Leukemias (EGIL) criteria; group 3 included patients diagnosed using either the EGIL or the 2008/2016 WHO criteria; and group 4 was comprised of patients diagnosed with MPAL using the EGIL classification only.ResultsWe found a significantly worse disease-free survival (groups 1-4) and overall survival (OS) (groups 2 and 3) when comparing MPAL patients to other acute leukemia (AL) patients. A significantly better OS was obtained in patients (groups 2-4) treated with ALL-type chemotherapy compared to acute myeloid leukemia (AML)-type regimens.ConclusionIn light of these results, and because a trend (P=0.06) was found with regard to a better OS in group 4 when compared to other AL patients, an argument can be made that the 2008/2016 WHO classification is underpowered to diagnose all MPAL cases, potentially resulting in the suboptimal treatment of some individuals with AL.

show abstract

“…In contrast, microRNA profiling studies suggest that MPAL does not appear to be a distinct entity. de Leeuw et al 32 analyzed 16 cases of acute leukemia of ambiguous lineage and demonstrated that all cases had microRNA expression profiles that clustered with AML or ALL. Heesch et al 33 noted a higher expression of BAALC and ERG-adverse prognostic characteristics in AML-in 26 cases of EGIL-defined BAL compared with other cases of AML.…”

Section: Genetic Alterations In Mpalmentioning

confidence: 99%

How I treat mixed-phenotype acute leukemia

Wolach

Stone

2015

Blood

132

139

View full text Add to dashboard Cite

Mixed-phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. A variety of different terms and classification systems have been used historically to describe this entity. MPAL is currently defined by a limited set of lineage-specific markers proposed in the 2008 World Health Organization monograph on classification of tumors of hematopoietic and lymphoid tissues. In adult patients, MPAL is characterized by relative therapeutic resistance that may be attributed in part to the high proportion of patients with adverse cytogenetic abnormalities. No prospective, controlled trials exist to guide therapy. The limited available data suggest that an “acute lymphoblastic leukemia–like” regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyrosine kinase inhibitor in patients with t(9;22) translocation is recommended. The role of immunophenotypic and genetic markers in guiding chemotherapy choice and postremission strategy, as well as the utility of targeted therapies in non–Ph-positive MPALs is unknown.

show abstract

MicroRNA Profiling Can Classify Acute Leukemias of Ambiguous Lineage as Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia

Cited by 38 publications

References 28 publications

Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma

Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma

Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used

How I treat mixed-phenotype acute leukemia

Contact Info

Product

Resources

About